We then overexpressed CSF-1 in epithelial 4NQO-L cells and evaluated the tumor response to trametinib in vivo, including profiling the number of MDSCs expressing CD11c+ and CD8+ T cells in the tumor. Here, ITGAX is linked to neoplasm.